US6701002056 - ADR
91.3 +0.01 (+0.01%)
After market: 91.53 +0.23 (+0.25%)
NOVO-NORDISK A/S-SPONS ADR
NYSE:NVO (9/22/2023, 7:16:28 PM)After market: 91.53 +0.23 (+0.25%)
Find more stocks on New York Stock Exchange, Inc.
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Novo Nordisk A/S is a DK-based company operating in Pharmaceuticals industry. Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
NOVO-NORDISK A/S-SPONS ADR
Novo Alle 1
CEO: Lars Fruergaard Jorgensen
Treasury yields surged to long-term highs, while leading stocks buckled.
Weight-loss treatments are a big part of Novo Nordisk's business and could be key to its growth for years to come.
In the world of growth stocks, NYSE:NVO shines as a value proposition.
A downbeat analyst take resonated with investors.
The company says it has since corrected the issues found in the FDA inspection.
The good news outweighed the bad for the hot drug developer on Hump Day.
Here you can normally see the latest stock twits on NVO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.